

Publication

Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

ID 4514961

Author(s) Navarini, Alexander A.; French, Lars E.

Author(s) at UniBasel [Navarini, Alexander](#) ;

Year 2018

Title Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice

Journal The Journal of Investigative Dermatology

Volume 138

Number 4

Pages / Article-Number 726-728

Mesh terms Biological Products; Biological Therapy; Cohort Studies; Dermatologists; Humans; Psoriasis; Quality of Life; Registries

Psoriasis is one of the most chronic diseases in dermatology. Only a small percentage of patients ever experience relapse-free survival. The constant presence of plaques and comorbidities that affect the cardiovascular system, joints, and other organs greatly impair patients' quality of life. In addition, the life expectancy of psoriatic patients is shortened by several years. Hence, long-term and ideally systemic treatment with minimal adverse effects may be warranted.

Publisher ELSEVIER SCIENCE INC

ISSN/ISBN 1523-1747

edoc-URL <https://edoc.unibas.ch/72198/>

Full Text on edoc No;

Digital Object Identifier DOI 10.1016/j.jid.2018.02.008

PubMed ID <http://www.ncbi.nlm.nih.gov/pubmed/29579453>

ISI-Number WOS:000428135400006

Document type (ISI) Journal Article, Comment